Inmeta focuses on major diseases and provides high-quality, innovative diagnosis and treatment solutions for clinics. The company’s product line focuses on digestive tract/respiratory tract tumors and cardiovascular diseases. Recently announced the completion of the D round of equity financing, with a financing amount of nearly 300 million yuan. This round of financing was led by Songhe Capital and Simiao Capital, with Co-Stone Investment, Chengshang Investment, Minsheng Securities’ funds, Huataixin Medical Investment Fund, Dietze Investment, Anxin Light Salt Pharmaceutical and Health Industry Investment Fund, and Longgang Financial Holdings as follow-up investors. This round of financing will be used to develop and consolidate the research and development of innovative product lines, capacity building, market expansion and team building.
This article is transferred from: https://www.itjuzi.com/investevent/13726265
This site is only for collection, and the copyright belongs to the original author.